Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Change in Inventory (2019 - 2025)

Akebia Therapeutics (AKBA) has disclosed Change in Inventory for 7 consecutive years, with $17.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Inventory rose 105.01% to $17.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $23.1 million, a 18.58% decrease, with the full-year FY2025 number at $23.1 million, down 18.58% from a year prior.
  • Change in Inventory was $17.4 million for Q4 2025 at Akebia Therapeutics, up from -$6.9 million in the prior quarter.
  • In the past five years, Change in Inventory ranged from a high of $19.2 million in Q1 2021 to a low of -$24.5 million in Q4 2022.
  • A 5-year average of $3.0 million and a median of $3.0 million in 2023 define the central range for Change in Inventory.
  • Biggest YoY gain for Change in Inventory was 765.2% in 2021; the steepest drop was 4201.19% in 2021.
  • Akebia Therapeutics' Change in Inventory stood at -$10.3 million in 2021, then plummeted by 136.59% to -$24.5 million in 2022, then skyrocketed by 148.18% to $11.8 million in 2023, then fell by 27.88% to $8.5 million in 2024, then surged by 105.01% to $17.4 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Change in Inventory are $17.4 million (Q4 2025), -$6.9 million (Q3 2025), and $7.7 million (Q2 2025).